- Home
- OCG vs PPBT Comparison
OCG vs PPBT Comparison
Compare OCG & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCG | PPBT |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.9M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OCG | PPBT |
|---|---|---|
| Price | $0.85 | $4.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 291.0K | 13.3K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | ★ 6.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.41 |
| 52 Week High | $19.29 | $5.18 |
Technical Indicators
Market Signals| Indicator | OCG | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 68.76 |
| Support Level | $0.57 | $0.57 |
| Resistance Level | $1.09 | $5.18 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 97.62 | 84.45 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.